Castle’s DecisionDx-Melanoma Test Outperforms Staging and CP-GEP in Identifying Patients at Low Risk of SLN Positivity
DecisionDx-Melanoma outperforms both American Joint Committee on Cancer (AJCC) staging and the CP-GEP test (clinicopathological and gene expression profiling model) in identifying patients at low risk of sentinel lymph node (SLN) positivity who may consider forgoing sentinel lymph node biopsy (SLNB) surgery.